Novartis withdraws EU Rasival submission
This article was originally published in SRA
Executive Summary
Novartis Europharm has withdrawn a submission for centralised EU marketing authorisation of its hypertension combination Rasival (aliskiren plus valsartan), even though the drug has already been approved in the US as Valturna1.